Evolving Supplement Landscape: Quality, AI, and Regulation Drive Industry Shifts

Decoding the Supplement Industry's Evolution

As contract manufacturers, we're constantly monitoring the pulse of the dietary supplement industry, and recent insights from Elan Sudberg, CEO of Alkemist Labs, in Nutraceuticals World's 2026 State of the Industry review, certainly resonate with our observations. He highlights a fundamental 'reorganisation of the industry's DNA' driven by a confluence of factors: enhanced transparency, scientific advancements, and the integration of artificial intelligence.

For too long, certain aspects of quality and accountability have operated in a grey area. However, there's a tangible shift towards greater rigour. Sudberg points to the 'MAHA movement' – a push for 'make all health care affordable' and consumer empowerment – as a quiet force reshaping expectations. This isn't just about healthcare access; it's about consumers scrutinising product claims, demanding to know 'what's in here and how do you know?', a question that, for manufacturers like us, is central to our operations. When a major brand like AG1 openly shares its quality playbook, it sets a new benchmark. Brand owners unable to demonstrate similar transparency risk falling behind in a market increasingly valuing proof over promises.

Manufacturing Challenges and Opportunities in a Shifting Market

From a formulation standpoint, the continued dominance of gummies, while excellent for consumer adherence, presents a dual challenge. Their popularity means manufacturers must overcome inherent hurdles such as 'potency drift' and 'active stability' during production. These require sophisticated manufacturing processes and rigorous quality checks to ensure the delivered product matches the label claims, especially given the various stability profiles of active ingredients. Consumers love the convenience, but it's our responsibility to ensure the efficacy isn't compromised by the format.

Regulatory oversight is also tightening. Sudberg notes that initiatives like Amazon's Big TIC (testing, inspection, certification) program, while well-intentioned, require consistent and robust enforcement to be truly effective. The concern is that inconsistent application of standards allows 'bad actors' to persist, undermining the efforts of compliant manufacturers. We anticipate – and welcome – more comprehensive FDA inspections and clearer guidance for 483s and warning letters. This isn't about 'gotchas' but about elevating industry standards, creating a level playing field where quality and scientific integrity are key differentiators.

"Expect AI to move from novelty to necessary, especially in formulation. Winners won’t 'replace' R&D with AI; they’ll embed it as a copilot — accelerating literature reviews and narrowing ingredient sets."

The Future is Smart and Sustainable

Perhaps one of the most exciting developments is the rise of AI as a 'copilot' in R&D. For us and our clients, this means unprecedented opportunities to accelerate discovery, optimise formulations, and even predict consumer trends. AI won't replace human expertise but augment it, making product development faster, more precise, and more cost-effective. Brand owners should begin to explore how AI can be integrated into their innovation cycles.

Finally, the 'shroom boom' continues to expand beyond traditional capsules into various innovative formats like beverages and chews. This trend demands tighter specifications for active compounds and clear differentiation between mycelium and fruiting body extracts, requiring advanced analytical capabilities and a deep understanding of raw material sourcing. The threads of accountability, transparent quality, effective marketplace enforcement, and AI-driven innovation are weaving together to define the next chapter of the supplement industry.

Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.